Takeda Pharmaceutical Company Limited FY2026 FY Earnings Report

Financial Highlights

• Net Sales: ¥4.51T
• Operating Income: ¥408.76B
• Net Income: ¥192.03B
• EPS: ¥121.75

Income Statement

Balance Sheet

Cash Flow Statement

Profitability Ratios

Year-over-Year Comparison

Share Information

Dividend Information

Full Year Forecast

---

AI Financial Analysis

Executive Summary

Takeda delivered a solid FY2026 under IFRS with margin-led profit growth despite a slight top-line decline. Revenue fell 1.7% to 4,505.7bn JPY, but operating income rose 19.3% to 408.8bn JPY, expanding the operating margin to 9.1%. Net income increased 77.6% to 192.0bn JPY, lifting the net margin to 4.3%. Gross margin was 65.1%, marginally lower than last year, while tighter operating cost discipline (lower R&D intensity and SG&A ratio) drove margin leverage. Operating margin expanded by about 159 bps YoY (from 7.5% to 9.1%), and net margin improved by roughly 190 bps (from 2.4% to 4.3%). Ordinary income more than doubled (+137% YoY) despite a high interest burden, supported by increased finance income and stronger operating results. Cash generation was very strong: operating cash flow reached 1,041.4bn JPY, equating to 5.4x net income, and free cash flow was 672.3bn JPY. The balance sheet strengthened with total equity up to 7,774.8bn JPY (equity ratio 50.3%), though goodwill rose to 5,809.0bn JPY (74.7% of equity), underscoring impairment sensitivity. Liquidity remains adequate with a current ratio around 1.27x and cash of 595.1bn JPY exceeding short-term borrowings of 512.2bn JPY. Debt-to-equity is 0.99x; interest burden is heavy (interest burden factor 0.64), keeping coverage only moderate. Inventory days are elevated at 324, calling for working capital vigilance. On capital returns, DPS totaled 200 JPY versus EPS of 121.75 JPY (payout ratio ~164–166%), but dividends were covered 2.1x by free cash flow. Versus management guidance, operating income landed slightly below the 420bn JPY target, while profit attributable to owners exceeded the 166bn JPY forecast. Overall, results show improved operating efficiency and robust cash conversion, offset by a high goodwill base, elevated inventory, and leverage-driven interest drag. Looking forward, sustaining margin gains while normalizing inventories and reducing net interest outflows will be key to improving ROE and ROIC.

Profitability Analysis

ROE decomposition (3-factor): ROE ≈ Net Profit Margin (4.3%) × Asset Turnover (0.292x) × Financial Leverage (1.99x) ≈ 2.5–2.6%. The largest YoY change came from net margin expansion, driven by operating margin improvement to 9.1% and a higher finance income contribution partially offsetting finance costs. Business drivers included lower R&D intensity (15.0% of sales vs 16.0% previously), leaner SG&A ratio (24.0%), and reduced other operating expenses. Interest burden remained high (EBT/EBIT 0.64) due to finance costs of 357.6bn JPY versus finance income of 211.2bn JPY. Margin gains look partly sustainable given cost discipline, but interest drag may persist until debt is reduced or refinanced. SG&A and R&D grew below sales (declines in absolute yen), indicating positive operating leverage.

Growth Assessment

Revenue declined 1.7% YoY to 4,505.7bn JPY, while operating income rose 19.3% to 408.8bn JPY and net income rose 77.6% to 192.0bn JPY. Growth was quality-led via cost optimization and lower R&D ratio, not via top-line expansion. Gross margin dipped slightly, but operating margin improved materially. Finance income increased significantly, aiding bottom line despite higher finance costs. Outlook hinges on sustaining cost efficiency and execution on late-stage pipeline to re-accelerate sales growth while maintaining margin discipline.

Financial Health

• Liquidity: Current assets 3,090.5bn JPY vs current liabilities 2,429.5bn JPY imply a current ratio of ~1.27x; cash (595.1bn JPY) covers short-term borrowings (512.2bn JPY).
• Solvency: Debt-to-equity 0.99x; noncurrent borrowings increased to 4,369.7bn JPY, keeping leverage moderate but interest-heavy. Equity ratio improved to 50.3%.
• Maturity profile: Limited near-term refinancing risk given cash and OCF; however, high total borrowings sustain interest burden.
• Off-balance: None highlighted beyond standard IFRS disclosures.

Notable B/S Changes

Goodwill: +485.6bn (+9.1%) - Increases M&A-dependent asset base; elevates future impairment risk. Intangible assets: -211.8bn (-5.8%) - Reflects amortization/impairment exceeding additions; monitor product life cycles. Cash and equivalents: +209.9bn (+54.5%) - Strengthened liquidity from robust OCF. Bonds and borrowings (noncurrent): +403.4bn (+10.2%) - Higher structural leverage sustaining interest burden. Deferred tax assets: +117.1bn (+31.6%) - Tax attribute build; may reflect FX and timing differences. Inventories: +179.3bn (+14.7%) - Ties up working capital; raises obsolescence risk with 324 DIO. Other components of equity (OCI): +945.5bn (+40.2%) - Large FX translation gains boosted equity. Other financial liabilities (current): -77.9bn (-35.5%) - Lower short-term derivative/financial obligations reduces near-term liabilities. Property, plant and equipment: +152.5bn (+7.7%) - Capacity and manufacturing investments progressing.

Cash Flow Quality

• OCF/Net Income: 5.43x indicates very high earnings quality.
• Free cash flow: 672.3bn JPY, sufficient to fund dividends (311.9bn JPY) and buybacks (51.6bn JPY) with headroom.
• Working capital: Inventories increased by 61.3bn JPY within the year; DIO at 324 days suggests potential cash tie-up risk if demand normalizes slower than expected.
• Cash conversion: Strong, supported by large non-cash charges (D&A 721.1bn JPY) and hedge settlements; no signs of aggressive working capital pull-forward.

Dividend Sustainability

• DPS: 200 JPY (100+100); EPS 121.75 JPY implies payout ratio ~164–166% on an earnings basis.
• FCF coverage: 2.11x, indicating cash support for current dividend despite high accounting payout.
• Total return: Dividends (311.9bn JPY) plus buybacks (51.6bn JPY) totaled ~363.5bn JPY, exceeding net income (192.0bn JPY); sustainable near term given FCF, but medium-term sustainability depends on maintaining strong OCF and managing interest costs.

Risk Assessment

Business risks include Pipeline and R&D execution risk: sustaining R&D productivity at ~15% intensity is critical to offset future LOEs., Pricing pressure across major markets could cap margin expansion., High inventory days (324) increase risk of obsolescence and working capital strain..

Financial risks include High interest burden (EBT/EBIT 0.64) due to sizable borrowings; interest coverage only moderate., Goodwill concentration risk: Goodwill/Equity at 74.7% heightens impairment sensitivity to forecast shortfalls., FX translation volatility: large positive OCI this year (exchange differences 903.9bn JPY) indicates material equity swings..

Key concerns include ROIC at 3.9% below cost of capital signals value creation challenge absent further margin or growth improvements., Inventory normalization path given elevated DIO could affect cash conversion if sales mix shifts., Dependence on cost controls for earnings growth with limited top-line momentum this year..

Investment Implications

Key takeaways include Margin-led earnings improvement with operating margin up ~160 bps to 9.1%., Very strong cash generation (OCF 1.04tn JPY; FCF 0.67tn JPY) supports shareholder returns., Leverage-driven interest drag and goodwill concentration remain structural overhangs., Inventory days at 324 warrant close monitoring for write-down or cash tie-up risk., Dividend well covered by FCF but high on an earnings basis; sustainability linked to continued cash strength..

Metrics to watch include Interest coverage and net finance costs trajectory, Inventory days and inventory-to-sales ratio, R&D intensity and late-stage pipeline milestones, Operating margin sustainability, Goodwill balance vs impairment testing outcomes.

Regarding relative positioning, Within global pharma peers, Takeda’s R&D intensity is aligned with innovator benchmarks and cash generation is strong, but ROE/ROIC trail peers due to elevated goodwill and interest burden; focus remains on pipeline execution and capital structure optimization to close the return gap.